全文获取类型
收费全文 | 1934404篇 |
免费 | 149762篇 |
国内免费 | 23620篇 |
专业分类
耳鼻咽喉 | 23647篇 |
儿科学 | 57771篇 |
妇产科学 | 48982篇 |
基础医学 | 271136篇 |
口腔科学 | 52722篇 |
临床医学 | 186686篇 |
内科学 | 365891篇 |
皮肤病学 | 40829篇 |
神经病学 | 144815篇 |
特种医学 | 72937篇 |
外国民族医学 | 440篇 |
外科学 | 279956篇 |
综合类 | 81836篇 |
现状与发展 | 77篇 |
一般理论 | 558篇 |
预防医学 | 138404篇 |
眼科学 | 47916篇 |
药学 | 150312篇 |
300篇 | |
中国医学 | 19886篇 |
肿瘤学 | 122685篇 |
出版年
2021年 | 26282篇 |
2020年 | 18416篇 |
2019年 | 22478篇 |
2018年 | 29257篇 |
2017年 | 23459篇 |
2016年 | 24415篇 |
2015年 | 30766篇 |
2014年 | 40711篇 |
2013年 | 49994篇 |
2012年 | 70680篇 |
2011年 | 76142篇 |
2010年 | 45394篇 |
2009年 | 40416篇 |
2008年 | 64242篇 |
2007年 | 67587篇 |
2006年 | 68307篇 |
2005年 | 65931篇 |
2004年 | 58597篇 |
2003年 | 55408篇 |
2002年 | 52445篇 |
2001年 | 96677篇 |
2000年 | 99237篇 |
1999年 | 83533篇 |
1998年 | 24211篇 |
1997年 | 21842篇 |
1996年 | 20975篇 |
1995年 | 20167篇 |
1994年 | 18110篇 |
1993年 | 15970篇 |
1992年 | 59329篇 |
1991年 | 56889篇 |
1990年 | 54342篇 |
1989年 | 51900篇 |
1988年 | 47081篇 |
1987年 | 45700篇 |
1986年 | 42799篇 |
1985年 | 40472篇 |
1984年 | 29583篇 |
1983年 | 24996篇 |
1982年 | 13917篇 |
1979年 | 25534篇 |
1978年 | 17528篇 |
1977年 | 14849篇 |
1976年 | 13829篇 |
1975年 | 14513篇 |
1974年 | 17601篇 |
1973年 | 16907篇 |
1972年 | 15664篇 |
1971年 | 14433篇 |
1970年 | 13415篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
Yan Gao Shi-Feng Chu Zhao Zhang Qi-Di Ai Cong-Yuan Xia Hui-Yong Huang 《Journal of Asian natural products research》2019,21(8):782-797
Inappropriate use of acetaminophen (APAP) can lead to morbidity and mortality secondary to hepatic necrosis. Ginsenoside Rg1 is a major active ingredient in processed Panax ginseng, which is proved to elicit biological effects. We hypothesized the beneficial effect of Rg1 on APAP-mediated hepatotoxicity was through Nrf2/ARE pathway. The study was conducted in cells and mice, comparing the actions of Rg1. Rg1 significantly improved cell survival rates and promoted the expression of antioxidant proteins. Meanwhile, Rg1 reduced the excessive ROS and the occurrence of cell apoptosis, which were related to Nrf2/ARE pathway. Expression of Nrf2 has a certain cell specificity.
53.
54.
55.
56.
57.
Widder Randolf A. Lappas Alexandra Rennings Corinna Hild Matthias Roessler Gernot F. Dietlein Thomas S. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(11):2581-2581
Graefe's Archive for Clinical and Experimental Ophthalmology - The published online version contains mistake as the author's first name and last name have been interchanged as "Hild... 相似文献
58.
59.
Philip S. Vendittelli Bassent Botros Howard S. Rosman Viren Govindaraju Anwar Zaitoun Tariq S. Marroush 《The American journal of the medical sciences》2019,357(4):333-337
Coronary embolism (CE) is an uncommon and unique cause of acute myocardial infarction. In this report, we review 216 cases of CE including 2 new cases from our institution. The mean patient age was 52.5 years and 62% of the patients were males. Chest pain was the most common presenting symptom followed by dyspnea, and the most commonly affected vessel was the left anterior descending artery. Leading etiologies of the embolus were atrial fibrillation, septic emboli, and iatrogenic causes. Treatment approaches varied with thrombus aspiration being used in 30% of cases. In-hospital mortality rate was 36% and 13% of the cases were complicated by cerebrovascular accident. CE is a unique pathology that leads to acute myocardial infarction. It portends a high mortality rate and requires a high level of suspicion as symptoms may be misleading. Further research is needed in order to improve recognition and management and to lower associated mortality. 相似文献
60.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献